Here’s a breakdown of the key information from the provided article:
Study Summary:
* What was studied: A shelf-stable, cryopreserved amniotic membrane was tested for its effectiveness in treating ocular surface disease. Traditionally, these membranes needed to be kept frozen. This new version can be stored at room temperature.
* results:
* Rapid corneal healing was observed.
* Trace staining remained in 3 eyes, while 5 eyes showed complete resolution.
* 65% of eyes showed symptomatic improvement (resolution of at least one symptom).
* Complications were minimal: irritation in 3 cases (2 related to a collagen shield, 1 to adhesive tape).
* Importance: This shelf-stable membrane makes advanced ocular surface therapy more accessible and convenient.
Key People & Affiliations:
* Sean P. Cushman, OD, FAAO: Lead the study. Contact: scushman@theeyeinstitute.com
* Rodger Kennedy: Senior Director of Marketing, BioTissue Ocular.
* BioTissue Ocular: The company that developed the shelf-stable amniotic membrane.
* The Eye Institute of Utah: Received an educational grant from BioTissue Holdings for the study.
Disclosure Information:
* Dr. Cushman is a speaker for Bausch + Lomb.
* Rodger Kennedy is an employee of BioTissue Ocular.
* The Eye Institute of utah received funding from BioTissue Holdings.
Source:
* The study was published in Clin Optom (2025) with DOI: 10.2147/OPTO.S563708.
Additional Information:
* The article highlights the potential of “Healio AI” for accessing clinical information.
* The article was published by Primary Care Optometry News.
